Recently, new agents such as neprilysin inhibitor, sacubitril, or hyperpolarization-activated cyclic nucleotide-gated channel inhibitor, ivabradine, have emerged, and their efficacy for improving long-term prognosis in patients with chronic heart failure is expected. This evidence concerns the gene MME and congestive heart failure.